1	PRavastatin Or atorVastatin Evaluation and Infection Therapy (TIMI 22)
2	Background Statin therapy is highly effective vs. placebo in long-term treatment of CHD Are statins effective in reducing events in patients with an acute coronary syndrome (ACS)? Does “intensive” LDL-C lowering to an average of 65 mg/dL achieve a greater reduction in clinical events than “standard” LDL-C lowering to an average of 95 mg/dL?
3	PROVE IT - TIMI 22: Study Design
4	Patient Population Inclusion Criteria: Hospitalization for acute MI or high-risk unstable angina < 10 d Total cholesterol < 240 mg/dL (< 200 mg/dL if on Lipid ¯ Rx) Stabilized (i.e., without ischemia, CHF, post PCI if performed) Major Exclusion Criteria: Co-morbidity: patient survival < 2 years Current therapy with simvastatin or atorvastatin 80 mg Need for, or anticipated use of fibrates or niacin CABG for treatment of qualifying ACS Liver disease or unexplained CK elevations Strong inhibitors of CYP450 3A4 (2^oatorvastatin metabolism)
5	Patient Enrollment by Country
6	Top Ten Enrolling Clinical Centers
7	Trial Organization
8
9
10
11
12	Primary Endpoint Over Time
13
14
15
16
17	Summary In patients recently hospitalized within 10 days for an acute coronary syndrome: “Intensive” high-dose LDL-C lowering (median LDL-C 62 mg/dL) compared to “moderate” standard-dose lipid-lowering therapy (median LDL-C 95 mg/dL) reduced the risk of all cause mortality or major cardiac events by 16% (p=0.005) Benefits emerged within 30 days post ACS with continued benefit observed throughout the 2.5 years of follow-up Benefits were consistent across all cardiovascular endpoints, except stroke, and most clinical subgroups
18	PROVE-IT Conclusion Our findings indicate that patients recently hospitalized for an acute coronary syndrome benefit from early and continued lowering of LDL-C to levels substantially below current target levels.